Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Indivior ( (INDV) ) has issued an announcement.
On December 12, 2025, Indivior PLC’s board approved base salary increases for its top executives, effective January 1, 2026, following a competitive market review and recommendations from its Compensation Committee and external consultants. Chief Executive Officer Joseph Ciaffoni’s annual base salary will rise from $1,050,000 to $1,115,000, while Chief Financial Officer Ryan Preblick’s base pay will increase from $559,000 to $604,000, signaling the company’s intention to retain and reward senior leadership amid ongoing market pressures in the pharmaceutical sector.
The most recent analyst rating on (INDV) stock is a Hold with a $40.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.
Spark’s Take on INDV Stock
According to Spark, TipRanks’ AI Analyst, INDV is a Neutral.
Indivior’s overall score reflects strong earnings call outcomes and positive corporate events, which are offset by financial stability concerns and a high valuation. The technical analysis indicates bullish momentum, though caution is advised due to overbought signals.
To see Spark’s full report on INDV stock, click here.
More about Indivior
Indivior PLC is a specialty pharmaceutical company focused on developing and commercializing therapies, particularly for the treatment of addiction and related mental health conditions, targeting patients and healthcare systems in global markets.
Average Trading Volume: 2,315,367
Technical Sentiment Signal: Buy
Current Market Cap: $4.42B
For detailed information about INDV stock, go to TipRanks’ Stock Analysis page.